Kornimate/medical-research-clean huggingface dataset:
applicability of uroflowmetry in children with cerebral palsy

Conditions: Cerebral Palsy; Lower Urinary Tract Symptoms

Summary: until now, the use of invasive urodynamics with use of catheters is still the gold standard for lower urinary tract evaluation in subjects with cp. this suggests a psychological and physical impact of invasive urodynamics in subjects with cp and further demonstrates the need to avoid standard use of invasive urodynamics in children and adults with cp. the current study will evaluate usefulness of uroflowmetry, correlation between uroflowmetry parameters and different lower urinary tract symptoms will be investigated. secondly, results of uroflowmetry indicating possible vulnerability of the upper urinary tract will be defined.

a cross-sectional case-control study comparing children with cp and luts and children with cp without luts will be conducted with the primary objective to investigate correlation between uroflowmetry parameters and different luts. children will be evaluated with uroflowmetry and subsequent post void residual measurement and the validated vancouver symptom score for dysfunctional elimination syndrome.

Eligibility criteria:
inclusion criteria: * diagnosis of cerebral palsy * dutch or french speaking child and parent exclusion criteria: * history of urological surgery

Keywords: cerebral palsy lower urinary tract symptoms incontinence uroflow measurement
clinical performance of the histidine rich protein 2 (hrp2) highly sensitive rapid diagnostic test (hs-rdt) for malaria diagnosis in pregnant women in papua new guinea

Conditions: Plasmodium Falciparum Malaria; Pregnancy Malaria; Diagnoses Disease

Summary: malaria during pregnancy remains an important public health issue in endemic countries. most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as well as low birth weight. infections that do not cause symptoms (sub-clinical infections) - particularly in low transmission settings -remain difficult to diagnose during pregnancy but can contribute to adverse outcomes e.g. growth restriction, premature birth, miscarriage and stillbirth. the bill \& melinda gates foundation (bmgf) has supported the development of an hrp2-based high sensitivity rapid diagnostic tests (hs-rdt) that has analytical sensitivity ten times better than current rdts and a sensitivity near 80% when compared to the 'gold standard' of quantitative polymerase chain reaction (qpcr). in this regard, the new hs-rdt may be a promising diagnostic and screening test for subclinical malaria during pregnancy. the overall aim is to compare the performance of novel high sensitivity rapid detection tests with conventional rapid diagnostic tests for plasmodium falciparum malaria infection in pregnant women in papua new guinea


Eligibility criteria:
inclusion criteria: * all women must meet all the following inclusion criteria in order to be eligible to participate in the study: * pregnant women attending first antenatal care visit at selected health facilities * resident in the study area for at least 1 year prior to enrolment * age ≥ 16 * willing to freely participate with signed informed consent (or, if illiterate, provide a thumbprint in the presence of an independent witness) * willing to provide finger-prick blood sample exclusion criteria: * women meeting any of the following exclusion criteria at screening will be excluded from study participation: * history of malaria or antimalarial drugs used in the last three months, as recalled or documented in health record * presence of severe malaria as defined by who guidelines at the moment of recruitment. presence of symptoms and signs of other serious chronic disease such as severe anaemia, tuberculosis and/or central nervous system infections, as defined by who guidelines

Keywords: malaria pregnancy diagnosis rapid diagnostic test
tracheal mechanics during bronchoscopy

Conditions: Tracheomalacia; Tracheobronchomalacia

Summary: the main purpose of this study is use a new type of measurement to help decide what kind of therapy would help people with a collapsing windpipe or tracheomalacia.

this study is to obtain new information about the pressures required to collapse the trachea in patients with and without obstructive pulmonary disease and to describe the relationship between pressures and airflow obstruction. this information will provide normative data not currently available and would establish whether tracheal collapse is due to tracheomalacia. the data may lead to better ways of predicting if a patient would benefit from procedures to prevent tracheal collapse.

Eligibility criteria:
inclusion criteria: * suspicion of tracheal collapse undergoing bronchoscopy * healthy control subject undergoing bronchoscopy for another purpose. exclusion criteria: * esophageal pathology * tracheostomy * inability to follow commands

Keywords: copd
psychological impact of covid-19 pandemic in healthcare workers

Conditions: Covid19; Stress, Psychological; Work Related Stress; Epidemic Disease; SARS-CoV Infection

Summary: background. the current coronavirus disease (covid-19) has a great impact worldwide. healthcare workers play an essential role and are one of the most exposed groups.information about the psychosocial impact on healthcare workers is limited. methods. 3109 healthcare workers completed a national, internet-based, cross-sectional 45-item survey between 9 and 19 april 2020. the objective is to assess the psychological impact of the covid-19 pandemic in spanish healthcare workers. a psychological stress and adaptation at work score (psas) was defined combining four modified versions of validated psychological assessment tests (a) healthcare stressful test, (b) coping strategies inventory,(c) font-roja questionnaire and (d) trait meta-mood scale.

psas (psychological stress and adaptation at work score) is a self conducted questionnaire designed to assess psychological impact in healthcare workers to match times of crisis and when the time is scarce. psas has a range between 0 and 105, and higher scores represent higher stress detected.

Eligibility criteria:
inclusion criteria: * active healthcare workers in any private/public hospital \> 18 years old exclusion criteria: * refusal to participate
treating oxidative stress in children with autism

Conditions: Autistic Disorder

Summary: an open label trial was undertaken in 40 autistic children to determine whether treatment with metabolic precursors methylcobalamin and folinic acid would improve plasma biomarkers of oxidative stress and measures of core behavior using the vineland adaptive behavior scales (vabs). metabolites involved in methionine and glutathione synthesis and vabs behavior scores were measured before and after a three month intervention period. the results indicated that pre-treatment metabolites in autistic children were significantly different from values in age-matched control children. the three month intervention resulted in significant increases in cysteine, cysteinylglycine, and glutathione (gsh, p \ 0.01). similarly, increases in vabs composite score and sub-scores for socialization, communication, and daily living skills increased after treatment (p \< 0.007) but also remained below standard scores.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of autistic disorder by dsm-iv 299.0 or cars score \>30 exclusion criteria: * primary genetic disease with co-morbid autism * frequent seizures * recent surgery * active infection with fever * high dose vitamin/mineral supplements * severe gastrointestinal symptoms

Keywords: glutathione methionine folinic acid redox oxidative stress behavior
a randomized controlled study of digitalized cognitive behavioral intervention for antenatal depression

Conditions: Depression; Antenatal Depression

Summary: the main objective of the current research project is to evaluate the effectiveness of the digitalized cognitive behavioral therapy program including telephone coaching for antenatal depressive symptoms. the participants are screened from the general population of pregnant women, as a part of the routine maternity health care check-ups. mothers with depressive symptoms will be randomized into intervention group receiving guided digitalized treatment program or control group receiving education material about depression in digital form.


Eligibility criteria:
inclusion criteria: * fluent in written and spoken finnish or swedish * access to computer or mobile phone with internet * between 12 and 22 weeks pregnant * screening and baseline score on the epds ≥10 points exclusion criteria: * lifetime history of psychotic disorder (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, psychotic depression) * active suicidal ideation * severe substance abuse or dependence * actively ongoing psychotherapy * participates in another intervention study aiming at treating the symptoms of antenatal depression * multiple pregnancy

Keywords: digital intervention cognitive behavioral therapy antenatal depression
the efficacy, tolerability and safety of donepezil (aricept) in parkinson's disease patients with dementia

Conditions: Dementia With Parkinson's Disease

Summary: a randomised, double-blind, 3-arm parallel group study comparing aricept® with placebo.


Eligibility criteria:
patients with an established diagnosis of pd and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study. best efforts must be made on clinical grounds to exclude patients with dlb and ad. the key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of pd.
suprachoroidal injection of cls-ta in patients with non-infectious uveitis

Conditions: Uveitis; Uveitis, Posterior; Uveitis, Anterior; Uveitis, Intermediate; Panuveitis

Summary: this open-label study is designed to evaluate the safety of suprachoroidally administered triamcinolone acetone injectable suspension, cls-ta, in patients with non-infectious uveitis with and without macular edema.

this is a phase 3, open-label multicenter study to assess the safety of 4 mg of cls-ta administered via suprachoroidal injection in the treatment of patients diagnosed with noninfectious uveitis with and without macular edema. qualified patients will be enrolled and receive two suprachoroidal injections of cls-ta administered to the study eye approximately 12 weeks apart (visit 2 and visit 5). follow-up visits will be conducted monthly up to 24 weeks (visit 8).

Eligibility criteria:
inclusion criteria: * diagnosis of active or inactive non-infectious uveitis (pan, anterior, intermediate and posterior) * etdrs bcva score of ≥ 5 letters read in the study eye exclusion criteria: * any active ocular disease or infection in the study eye other than uveitis * intraocular pressure \> 22 mmhg or uncontrolled glaucoma in the study eye; patients with iop of 22 or less in the study eye not excluded with no more than 2 iop-lowering medications. * any uncontrolled systemic disease that, in the opinion of the investigator, would preclude participation in the study * any topical ocular corticosteroid in the 10 days prior to baseline; intraocular or periocular corticosteroid injections in the 2 months prior to baseline; an ozurdex implant in the 6 months prior to baseline; retisert or iluvien implant in the 3 years prior to baseline.

Keywords: uveitis ume posterior uveitis anterior uveitis intermediate uveitis panuveitis non-infectious uveitis triamcinolone choroid choroidal injection suprachoroidal microneedle microinjection triamcinolone acetonide
nitrate supplementation on motor unit activity

Conditions: Dietary Supplements; Healthy

Summary: this study aimed to assess if nitrate supplementation influence motor unit (mu) activity following a sustained ischemic contraction and whether this is affected by blood flow restriction (bfr) during the recovery period. fourteen male participants (mean ± sd, 25 ± 6 years) completed two experimental trials following 5-days of supplementation with either nitrate-rich (nit) or nitrate-depleted (pla) beetroot juice in a randomized, double-blinded, cross-over design. intramuscular electromyography was used to assess mu potential (mup) size and firing rates (mufr) during a submaximal (25% mvc) sustained isometric contraction with bfr. these variables were also assessed during a 90 s recovery period with the first half completed with, and the second half completed without, bfr. nitrate supplementation can expedite the recovery of mup duration following a sustained ischemic contraction in healthy adults. these novel observations improve understanding of the effects of nitrate on the recovery of neuromuscular function post-exercise and might have implications for recovery of muscle contractile function.


Eligibility criteria:
inclusion criteria: * male between 18 - 30 years * free from known respiratory insufficiency, cardiovascular disease and neuro-musculo-skeletal problems at present or in the preceding 6 months. * having at least 5 years competitively (team) sport experience. exclusion criteria: * having cardiovascular disease, neuromuscular disease and any lower limb injury and treatment for chronic respiratory complaints.
a novel regimen for treatment and prevention of post-inflammatory hyperpigmentation in skin of color

Conditions: Post Inflammatory Hyperpigmentation

Summary: this is a single-center, prospective, non-blinded, non-randomized 12 week clinical study to evaluate the efficacy of a skinceuticals comprehensive skin care regimen in the reduction of post inflammatory hyperpigmentation (pih) in skin of color patients. the comprehensive regimen features the pigment balancing peel which combines glycolic acid, lactic acid, kojic acid, vitamin c, and emblica into a treatment that may improve skin discoloration. participants will supplement the pigment balancing peel with a 11 week regimen that includes the hydrating b5 gel, discoloration defense, lha cleansing gel, and brightening uv defense sunscreen.


Eligibility criteria:
inclusion criteria: * men and women ages 18+. * clinical diagnosis of post inflammatory hyperpigmentation * non-caucasian * fitzpatrick skin types iv-vi * available and willing to comply with study instructions and attend all study visits. * able and willing to provide written and verbal informed consent. exclusion criteria: * subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy. * caucasian/ non-hispanic * subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. * pregnant, lactating, or is planning to become pregnant during the study. * subject is currently enrolled in an investigational drug or device study. * subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline). * study participant has facial hair that could interfere with the study assessments in the opinion of the investigator. * study participant is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. * subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles. * subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.

Keywords: skin of color post inflammatory hyperpigmentation skinceuticals
boric acid in degree 2 furcation defect

Conditions: Chronic Periodontitis With Mandibular Degree 2 Furcation Defects

Summary: the purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of subgingival delivery of boric acid gel as an adjunct to scaling and root planing (srp) on clinical and radiographic parameters and compare this method with srp plus placebo gel alone in patients with chronic periodontitis (cp).

background: the purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of subgingival delivery of boric acid gel as an adjunct to scaling and root planing (srp) on clinical and radiographic parameters and compare this method with srp plus placebo gel alone in patients with chronic periodontitis (cp). methods:forty eight systemically healthy patients with cp are included in this study. they were divided into two groups: 1) srp + 0.75% boric acid gel (ba group); 2) srp + placebo gel (placebo group). at baseline, 3 month, and 6 months after treatment, clinical measurements, including plaque index (pi), modified sulcus bleeding index (msbi), probing depth (pd), clinical attachment level (cal) and radiographic parameters intrabony defect depth (ibd), percentage change in radiographic defect depth reduction (ddr%) were assessed.

Eligibility criteria:
inclusion criteria: * presence of buccal class ii furcation defects in endodontically vital, asymptomatic mandibular first and second molars with a radiolucency in the furcation area on an intraoral periapical radiograph with probing depth (pd) ≥ 5mm and horizontal ≥ pd 3mm after phase i therapy i.e, scaling and root planing (srp) * no history of antibiotic or periodontal therapy in the preceding 6 months exclusion criteria: * systemic conditions known to affect the periodontal status * medications known to affect the outcomes of periodontal therapy * hematological disorders and insufficient platelet count (\<200,000/mm3) * pregnancy/lactation * smoking and tobacco use in any form * immunocompromised individuals * those having unacceptable oral hygiene (plaque index \[pi\] \>1.5) * teeth with furcation involvement, non-vital teeth, and carious teeth indicated for restorations and mobility of at least grade ii * aggressive periodontitis
liposomal bupivacaine vs. bupivacaine hydrochloride and lidocaine during suburethral sling placement

Conditions: Postoperative Pain

Summary: postoperative pain, the quality of their recovery and the opioid consumption following a midurethral sling placement are being compared between 2 groups. one group will have the hydro-dissection performed with a diluted liposomal bupivacaine solution. the other group will have the hydro-dissection performed with a diluted bupivacaine hcl and lidocaine solution.

this is a prospective, comparative, randomized study. women with pure stress urinary incontinence or mixed urinary incontinence with a predominant stress component who had chosen to proceed with a midurethral sling will be randomized to two groups. the study group will have the hydro-dissection performed with a diluted liposomal bupivacaine solution. the comparison group would have the hydro-dissection performed with a diluted bupivacaine hcl and lidocaine solution. the postoperative pain will be compared between groups using a visual analog scale. the quality of recovery will be compared between the groups using the quality of recovery short form. postoperative opioid consumption will be compared between the two groups.

Eligibility criteria:
inclusion criteria: * asa physical status i-iii * age \>18 years * not pregnant * able to give informed consent * electively chose surgical management of sui with a suburethral sling exclusion criteria: * pregnant or nursing * allergy to amide anesthetics * history of drug or alcohol abuse * severe cardiovascular, hepatic, renal disease or neurological impairment, * long-acting opioid within 3 days or any opioid use within 24 hours before surgery * patients taking monoamineoxidase inhibitors (maoi) or antidepressants of the triptyline or imipramine types * contraindication to: acetaminophen, non-steroidal anti-inflammatory drugs (nsaid), hydrocodone, oxycodone, hydromorphone and morphine, * administration of an investigational drug within 30 days before this study * chronic pain syndromes * daily nsaid or opioid use * patients undergoing concomitant procedures

Keywords: anesthetics anesthetic effects mid-urethral sling
effects of exhalation valve on the lack of air and exercise tolerance in patients with copd

Conditions: COPD

Summary: the purpose of this study is to evaluate the effects of the application of expiratory positive airway pressure (epap) on dynamic hyperinflation, dyspnea and exercise tolerance in patients with chronic obstructive pulmonary disease (copd).

initially will be collected clinical and anthropometric data of the participants, and they are packaged in self-evaluation form. the evaluation of pulmonary function at rest (spirometry, body plethysmography and lung diffusion capacity for carbon monoxide) will be rescued from patient charts. when carried out for over six months, will be repeated by the researchers. patients will conduct incremental cpet of 5-10w / min limited by symptoms (fev1 \ 1l - 10w) (visit 1). after a period of 2-7 days the cpet will be performed submaximal with 75% of the peak load reached in the incremental cpet (visits 2 and 3). the application of epap (10cmh2o) via face mask (vital rhdson signs®, new jersey, usa) will be randomized with the help of opaque envelopes to be given in one visit. during the visit without epap will be maintained using the facial mask applied without resistance. ic serial measurements will be carried out before, during and immediately after the exercise. participants will be instructed to maintain the use of long-acting bronchodilator as prescribed by the medical assistant usually before the methodological stages of the study.

Eligibility criteria:
inclusion criteria: * clinically stable patients without exacerbation of signs in the eight weeks preceding the study * making use of drug therapy (long-acting bronchodilators) * able to perform the exercise on the bike * without other comorbidities that compromise the results exercise * sign the informed consent exclusion criteria: * associated heart diseases * diagnosis of asthma * oxygen therapy use * spo2 \<85% at rest * use of oral corticosteroids or antihistamines * use of artificial airway * musculoskeletal dysfunction
intravitreal bevacizumab for nonproliferative diabetic retinopathy

Conditions: Non-proliferative Diabetic Retinopathy

Summary: in this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: intravitreal bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal bevacizumab, and control group (50 eyes) that undergo regular follow-up for diabetic retinopathy. diabetic macular edema (dme) will be treated independently in all groups by intravitreal bevacizumab. primary outcome will be the percentage of patients with progression of 2 or more stages through international diabetic retinopathy staging. the secondary measures will be changes in best corrected visual acuity (bcva) and central macular thickness (cmt), and number of examinations and injection.


Eligibility criteria:
inclusion criteria: * presence of severe npdr with drss score more than 53 with or without diabetic macular edema * diagnosis of dm (type 1 or 2) with age more than 18 years' old * visual acuity from 20/25 to 20/40 according to snellen chart examination or more than 69 letters according to etdrs chart exclusion criteria: * presence of proliferative diabetic retinopathy features including vitreous hemorrhage or optic disc or retinal neovascularization * history of retinal laser photocoagulation * tractional retinal detachment involving the macula * evidence of neovascularization of angle on examination * macular edema due to a cause other than dme * any ocular condition which may change visual acuity during the study * history of intravitreal injection of anti-vascular endothelial growth factor agent in past 3 months * history of any use of intravitreal corticosteroid * history of major intra-ocular surgery except cataract surgery in the past 6 months * history of thromboembolic every in the past 3 months